Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10029


The purpose of this study is to determine if Eculizumab is safe and effective in the prevention of delayed graft function following deceased donor kidney transplantation.

Study summary:

Based on experimental data and supportive observations in humans associating complement gene upregulation with ischemic reperfusion injury, it is hypothesized that C5 cleavage is a key step in the pathogenesis of ischemic reperfusion injury following transplantation. It is further hypothesized that eculizumab, an antibody that blocks C5 cleavage in humans will be an effective prophylactic agent to prevent ischemic reperfusion injury in high risk recipients. To test this hypothesis, this study is a pilot prospective, randomized study to test the efficacy of eculizumab vs. placebo given once at the time of transplantation in preventing delayed graft function in first adult recipients of deceased donor kidneys.


Inclusion Criteria: - Age 18 or older - Weight > 40 kg - Male or Female - Recipients of first deceased donor kidneys - Able to provide written informed consent - Transplant candidate as per site specific guidelines - Dialysis dependent renal failure (initiated more than 2 months prior to transplant) - Novartis Delayed Graft Function Score 3-8 - Extended criteria donor with brain death, or standard criteria donor with cold ischemic time < 24 hours Exclusion Criteria: - Planned to receive multi-organ transplant - Kidneys from donors < 6 years of age - Dual kidney transplant (from same donor, including en bloc) - Living donor kidney - Highly sensitized recipients (PRA > 50%) - Previous transplant - Participation in another investigational trial - Recipient BMI > 40 - ABO incompatible - DCD Donor - Preemptive kidney transplant - Recipients with DGF scores < 3 or > 8 - Women who are pregnant or breast feeding - Women of child bearing potential who are unable or unwilling to use a medically acceptable form of contraception - Patients infected with HIV, HCV or HBV - Active bacterial or other infection which is clinically significant in the opinion of the investigator - Patients with history of splenectomy - Patients with history of meningococcal disease - Patients with known or suspected hereditary complement deficiency - Patients with history of cancer (other than non-melanoma skin cancers) within the last 5 years



Primary Contact:

Principal Investigator
Bernd Schroppel, MD
Icahn School of Medicine at Mount Sinai

Backup Contact:


Location Contact:

New York, New York 10029
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.